Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1955 1
1959 1
1963 5
1964 2
1965 2
1969 1
1976 5
1977 2
1978 3
1979 3
1980 4
1981 7
1982 5
1983 2
1984 8
1985 15
1986 13
1987 12
1988 12
1989 12
1990 19
1991 15
1992 17
1993 21
1994 12
1995 13
1996 20
1997 22
1998 15
1999 14
2000 16
2001 12
2002 12
2003 17
2004 11
2005 14
2006 17
2007 17
2008 21
2009 31
2010 28
2011 31
2012 27
2013 37
2014 37
2015 49
2016 56
2017 54
2018 61
2019 68
2020 74
2021 91
2022 73
2023 67
2024 40

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,114 results

Results by year

Filters applied: . Clear all
Page 1
Ruxolitinib for Glucocorticoid-Refractory Chronic Graft-versus-Host Disease.
Zeiser R, Polverelli N, Ram R, Hashmi SK, Chakraverty R, Middeke JM, Musso M, Giebel S, Uzay A, Langmuir P, Hollaender N, Gowda M, Stefanelli T, Lee SJ, Teshima T, Locatelli F; REACH3 Investigators. Zeiser R, et al. Among authors: teshima t. N Engl J Med. 2021 Jul 15;385(3):228-238. doi: 10.1056/NEJMoa2033122. N Engl J Med. 2021. PMID: 34260836 Clinical Trial.
UCART19, a first-in-class allogeneic anti-CD19 chimeric antigen receptor T-cell therapy for adults with relapsed or refractory B-cell acute lymphoblastic leukaemia (CALM): a phase 1, dose-escalation trial.
Benjamin R, Jain N, Maus MV, Boissel N, Graham C, Jozwik A, Yallop D, Konopleva M, Frigault MJ, Teshima T, Kato K, Boucaud F, Balandraud S, Gianella-Borradori A, Binlich F, Marchiq I, Dupouy S, Almena-Carrasco M, Pannaux M, Fouliard S, Brissot E, Mohty M; CALM Study Group. Benjamin R, et al. Among authors: teshima t. Lancet Haematol. 2022 Nov;9(11):e833-e843. doi: 10.1016/S2352-3026(22)00245-9. Epub 2022 Oct 10. Lancet Haematol. 2022. PMID: 36228643 Free PMC article. Clinical Trial.
Ibrutinib for First-Line Treatment of Chronic Graft-Versus-Host Disease: Results From the Randomized Phase III iNTEGRATE Study.
Miklos DB, Abu Zaid M, Cooney JP, Albring JC, Flowers M, Skarbnik AP, Yakoub-Agha I, Ko BS, Bruno B, Waller EK, Yared J, Sohn SK, Bulabois CE, Teshima T, Jacobsohn D, Greinix H, Mokatrin A, Lee Y, Wahlstrom JT, Styles L, Socie G. Miklos DB, et al. Among authors: teshima t. J Clin Oncol. 2023 Apr 1;41(10):1876-1887. doi: 10.1200/JCO.22.00509. Epub 2023 Jan 6. J Clin Oncol. 2023. PMID: 36608310 Free PMC article. Clinical Trial.
Editorial.
Moroder L, Kiso Y, Diederichsen U, Teshima T. Moroder L, et al. Among authors: teshima t. J Pept Sci. 2017 Jul;23(7-8):471. doi: 10.1002/psc.3030. J Pept Sci. 2017. PMID: 28786204 No abstract available.
[GVHD and GVL].
Teshima T. Teshima T. Rinsho Ketsueki. 2009 Oct;50(10):1407-19. Rinsho Ketsueki. 2009. PMID: 19915349 Review. Japanese. No abstract available.
[Ara-C].
Onozawa M, Teshima T. Onozawa M, et al. Among authors: teshima t. Nihon Rinsho. 2015 Feb;73 Suppl 2:623-7. Nihon Rinsho. 2015. PMID: 25831835 Japanese. No abstract available.
1,114 results